BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 33823098)

  • 1. Blood pressure dynamics after pubertal suppression with gonadotropin-releasing hormone analogs followed by estradiol treatment in transgender female adolescents: a pilot study.
    Perl L; Elkon-Tamir E; Segev-Becker A; Israeli G; Brener A; Oren A
    J Pediatr Endocrinol Metab; 2021 Jun; 34(6):741-745. PubMed ID: 33823098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood Pressure Dynamics After Pubertal Suppression with Gonadotropin-Releasing Hormone Analogs Followed by Testosterone Treatment in Transgender Male Adolescents: A Pilot Study.
    Perl L; Segev-Becker A; Israeli G; Elkon-Tamir E; Oren A
    LGBT Health; 2020; 7(6):340-344. PubMed ID: 32735503
    [No Abstract]   [Full Text] [Related]  

  • 3. Bone Mineral Density in Transgender Adolescents Treated With Puberty Suppression and Subsequent Gender-Affirming Hormones.
    van der Loos MATC; Vlot MC; Klink DT; Hannema SE; den Heijer M; Wiepjes CM
    JAMA Pediatr; 2023 Dec; 177(12):1332-1341. PubMed ID: 37902760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of pubertal suppression and cross-sex hormone therapy on bone turnover markers and bone mineral apparent density (BMAD) in transgender adolescents.
    Vlot MC; Klink DT; den Heijer M; Blankenstein MA; Rotteveel J; Heijboer AC
    Bone; 2017 Feb; 95():11-19. PubMed ID: 27845262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Children and adolescents in the Amsterdam Cohort of Gender Dysphoria: trends in diagnostic- and treatment trajectories during the first 20 years of the Dutch Protocol.
    van der Loos MATC; Klink DT; Hannema SE; Bruinsma S; Steensma TD; Kreukels BPC; Cohen-Kettenis PT; de Vries ALC; den Heijer M; Wiepjes CM
    J Sex Med; 2023 Feb; 20(3):398-409. PubMed ID: 36763938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone Development in Transgender Adolescents Treated With GnRH Analogues and Subsequent Gender-Affirming Hormones.
    Schagen SEE; Wouters FM; Cohen-Kettenis PT; Gooren LJ; Hannema SE
    J Clin Endocrinol Metab; 2020 Dec; 105(12):e4252-63. PubMed ID: 32909025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of Hip Bone Geometry During Gender-Affirming Hormone Therapy in Transgender Adolescents Resembles That of the Experienced Gender When Pubertal Suspension Is Started in Early Puberty.
    van der Loos MA; Hellinga I; Vlot MC; Klink DT; den Heijer M; Wiepjes CM
    J Bone Miner Res; 2021 May; 36(5):931-941. PubMed ID: 33507568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in Adrenal Androgens During Puberty Suppression and Gender-Affirming Hormone Treatment in Adolescents With Gender Dysphoria.
    Schagen SEE; Lustenhouwer P; Cohen-Kettenis PT; Delemarre-van de Waal HA; Hannema SE
    J Sex Med; 2018 Sep; 15(9):1357-1363. PubMed ID: 30224022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trajectories of Adolescents Treated with Gonadotropin-Releasing Hormone Analogues for Gender Dysphoria.
    Brik T; Vrouenraets LJJJ; de Vries MC; Hannema SE
    Arch Sex Behav; 2020 Oct; 49(7):2611-2618. PubMed ID: 32152785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transgender Girls Grow Tall: Adult Height Is Unaffected by GnRH Analogue and Estradiol Treatment.
    Boogers LS; Wiepjes CM; Klink DT; Hellinga I; van Trotsenburg ASP; den Heijer M; Hannema SE
    J Clin Endocrinol Metab; 2022 Aug; 107(9):e3805-e3815. PubMed ID: 35666195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urological and Gynaecological Considerations for the Use of Gonadotropin-releasing Hormone Analogues in Transgender and Nonbinary Adolescents: A Narrative Review.
    Lee WG; Butler G; Carmichael P; Rashid T; Yasmin E; Morley R; Barrett J; Christopher N; Sangster P
    Eur Urol Focus; 2023 Jan; 9(1):35-41. PubMed ID: 36396559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pubertal Suppression, Bone Mass, and Body Composition in Youth With Gender Dysphoria.
    Navabi B; Tang K; Khatchadourian K; Lawson ML
    Pediatrics; 2021 Oct; 148(4):. PubMed ID: 34497118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Puberty Assessment and Consideration of Gonadotropin-Releasing Hormone Agonists in Transgender and Gender-Diverse Youth.
    Lee JY
    Pediatr Ann; 2023 Dec; 52(12):e462-e466. PubMed ID: 38049185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic Review: Puberty suppression with GnRH analogues in adolescents with gender incongruity.
    Ramos GGF; Mengai ACS; Daltro CAT; Cutrim PT; Zlotnik E; Beck APA
    J Endocrinol Invest; 2021 Jun; 44(6):1151-1158. PubMed ID: 33111215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in body mass index in children on gonadotropin-releasing hormone agonist therapy with precocious puberty, early puberty or short stature.
    Censani M; Feuer A; Orton S; Askin G; Vogiatzi M
    J Pediatr Endocrinol Metab; 2019 Oct; 32(10):1065-1070. PubMed ID: 31465296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of a Gonadotropin-releasing Hormone Analog to Treat Idiopathic Central Precocious Puberty Is Not Associated with Changes in Bone Structure in Postmenarchal Adolescents.
    Iannetta R; Melo AS; Iannetta O; Marchini JS; Paula FJ; Martinelli CE; Rosa e Silva AC; Ferriani RA; Martins WP; Reis RM
    J Pediatr Adolesc Gynecol; 2015 Oct; 28(5):304-8. PubMed ID: 26081481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth in Transgender/Gender-Diverse Youth in the First Year of Treatment With Gonadotropin-Releasing Hormone Agonists.
    Schulmeister C; Millington K; Kaufman M; Finlayson C; Kennedy JO; Garofalo R; Chan YM; Rosenthal SM
    J Adolesc Health; 2022 Jan; 70(1):108-113. PubMed ID: 34315674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term outcomes of pubertal suppression in a selected cohort of 12 to 15 year old young people with persistent gender dysphoria in the UK.
    Carmichael P; Butler G; Masic U; Cole TJ; De Stavola BL; Davidson S; Skageberg EM; Khadr S; Viner RM
    PLoS One; 2021; 16(2):e0243894. PubMed ID: 33529227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of gonadotropin releasing hormone analogue therapy on girls with gonadotropin-dependent precocious puberty.
    Tung YC; Lee JS; Tsai WY; Hsiao PH
    J Formos Med Assoc; 2007 Oct; 106(10):826-31. PubMed ID: 17964961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gonadotropin releasing hormone agonist treatment to increase final stature in children with precocious puberty: a meta-analysis.
    Li P; Li Y; Yang CL
    Medicine (Baltimore); 2014 Dec; 93(27):e260. PubMed ID: 25501098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.